Member Info for EarlofAim

Copper price going to be massive in coming weeks and months

IMC has copper waiting to be extracted.

GLA and Dyor before its too late

Crawshaw

Alan55

petroinvestor

all 3 of you should listen to Ria20 as she's best in class

😉or At least Do research on her calls

CMRS going to be massive very soon.... watch the space!

Well done investorAce

you proofed your winnings......

ria20 was spot on

o Crawshaw stop being silly, I'm not ria20 and most knows this.

ria20 is class act.....

be fortune to have ria20 on LSE, so much information she gives.

well done ria

Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

This AIM-traded firm said the development pertained to POLB 001, a potent phase II-ready p38 MAP kinase inhibitor with promising applications across various disease domains.

It said the approved claims by the US Patent Office encompassed a class of drugs, including POLB 001, intended for the treatment of hypercytokinemia, or cytokine storm, and prevention of hypercytokinemia post-immune response activation, applicable to cytokine storms induced by any disease indication.

Poolbeg said it was actively bolstering its intellectual property portfolio with existing patents covering p38 MAP kinase inhibitors for severe influenza treatment and POLB 001 specifically for hypercytokinemia treatment.

Additionally, the company said it had filed further patent applications to broaden coverage, particularly in cancer immunotherapies, thus augmenting the value and appeal of POLB 001 to potential pharmaceutical partners.

"This notice of allowance is significant for Poolbeg, further strengthening our robust intellectual property for the company's exciting POLB 001 therapy and enhancing its value for potential partners," said chief executive officer Jeremy Skillington.

"POLB 001 has the potential to make breakthrough cancer immunotherapies more accessible to the patients that need them by enabling safer and broader use of these cancer treatments in an outpatient setting.

"I am excited by the potential of POLB 001 to positively impact global health, it has a compelling data package and there is strong unmet need for an effective therapy for cancer immunotherapy-induced cytokine release syndrome with the market potential in this setting alone exceeding $10bn."

Wondering if where the next multi bagger coming from.... hmm

.....

already found it

it's a copper play that's the clue

mcap £650k

Morocco License

Placing done also

CMRS looks good to go on a run

Petroinvestor

he's my lucky charm, whenever he posts Sp goes vertical

look at the time Petroinvestor posted, since then Sp went nuts.

Rude to take profit when it this sort of rise.

swift Rises in the I like.......

Ria20

that was a fantastic call, yes jealous punters missed and calling out names that's really not very gentleman like from Alan55..... anyways

onto the next one...... won't mention here though.

don't need Alan55 to follow my Tips........

Ria20

well done dear...... that was a great call......

Is this truly a game-changer???

why sellers?

precursor to patent and Sp goes down.

looking to buy when this settles....

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented: "This Notice of Allowance is significant for Poolbeg, further strengthening our robust intellectual property for the Company's exciting POLB 001 therapy and enhancing its value for potential partners. POLB 001 has the potential to make breakthrough cancer immunotherapies more accessible to the patients that need them by enabling safer and broader use of these cancer treatments in an outpatient setting. I am excited by the potential of POLB 001 to positively impact global health, it has a compelling data package and there is strong unmet need for an effective therapy for cancer immunotherapy-induced Cytokine Release Syndrome with the market potential in this setting alone exceeding US$10 billion.

Https://www.voxmarkets.co.uk/rns/announcement/ea5ba077-b0cc-4587-9265-f80ea7f32b22/

Poolbeg Pharma plc

Poolbeg Pharma plc (POLB.L) Share Price & News

GBX 9.870

0.170 (1.72%)

Last updated 10:16

Price Snapshot

Last Trades

BID

9.600

-

10.000

ASK

HIGH

10.400

OPEN

10.150

VOL

1,300,693

MKT CAP

49.33M

LOW

9.610

CLOSE

9.700

SHARES IN ISSUE

500.00M

2W1M3M1Y

Profile

Financials

RNS

More...

Poolbeg Pharma plc RNS

March 20, 2024

07:00 POLB - Poolbeg Pharma PLC - POLB 001 US Patent Update

Twitter

February 22, 2024

07:00 POLB - Poolbeg Pharma PLC - Director/PDMR Shareholding

Twitter

February 19, 2024

13:42 POLB - Poolbeg Pharma PLC - Director Share Purchase

Twitter

February 15, 2024

07:00 POLB - Poolbeg Pharma PLC - Board Role Change and Launch of EIP

Twitter

February 12, 2024

07:00 POLB - Poolbeg Pharma PLC - Market Opportunity for POLB 001 for CRS

Twitter

January 17, 2024

07:00 POLB - Poolbeg Pharma PLC - Further data shows POLB001 potential in cancer CRS

Twitter

December 20, 2023

07:00 POLB - Poolbeg Pharma PLC - RSV AI Drug Candidate Analysis Update

Twitter

December 11, 2023

07:00 POLB - Poolbeg Pharma PLC - POLB 001 Data Presented at ASH

Twitter

November 30, 2023

07:00 POLB - Poolbeg Pharma PLC - Directorate Change

Twitter

November 21, 2023

07:00 POLB - Poolbeg Pharma PLC - Immunomodulator II patent granted in Japan

Twitter

November 16, 2023

07:00 POLB - Poolbeg Pharma PLC - POLB 001 LPS Trial Data to be Presented at IUIS

Twitter

November 09, 2023

07:00 POLB - Poolbeg Pharma PLC - Former Amryt Pharma Leadership Team join Poolbeg

Twitter

November 03, 2023

07:05 POLB - Poolbeg Pharma PLC - POLB001 Data to be Presented at ASH Annual Meeting

Twitter

November 01, 2023

07:00 POLB - Poolbeg Pharma PLC - POLB 001 Oncology Programme Update Meeting

Twitter

October 26, 2023

07:00 POLB - Poolbeg Pharma PLC - SAB Endorses Influenza Drug Targets

Twitter

October 17, 2023

07:00 POLB - Poolbeg Pharma PLC - Poolbeg Partners with a Nasdaq-Listed Biopharma

Twitter

September 29, 2023

07:00 POLB - Poolbeg Pharma PLC - Favourable Conclusion of Patent Opposition

Twitter

September 20, 2023

07:00 POLB - Poolbeg Pharma PLC - Immunomodulator I Patent Portfolio Strengthened

Twitter

September 19, 2023

07:00 POLB - Poolbeg Pharma PLC - Immunomodulator I Patent Opposition Withdrawal

Twitter

September 13, 2023

07:00 POLB - Poolbeg Pharma PLC - Interim results for the six months to 30 June 2023

Twitter

June 29, 2023

07:00 POLB - Poolbeg Pharma PLC - AI led programme identifies influenza drug targets

Twitter

June 22, 2023

07:00 POLB - Poolbeg Pharma PLC - Oral Vaccine Programme Moves Forward

Twitter

May 24, 2023

07:00 POLB - Poolbeg Pharma PLC - Board Appointment

Twitter

May 11, 2023

14:27 POLB - Poolbeg Pharma PLC - Results of Annual General Meeting

Twitter

April 12, 2023

07:00 POLB - Poolbeg Pharma PLC - Annual Report & AGM Notice

Twitter

March 30, 2023

07:00 POLB - Poolbeg Pharma PLC - Results for the year ended 31 December 2022

Twitter

March 10, 2023

07:00

I'm i reading this right..... £1Billion revenue

Nice article on critical minerals and resources Cmrsand copper

https://t.co/KFrhCnnF5p

Beginning of a bull Run on copper

cmrs looks good at these bargain SP

https://think.ing.com/articles/coppers-bull-run-is-only-just-beginning/

AI powered..... boom

not many seen this News yet!

That's huge news

Https://www.prnewswire.com/news-releases/mediamonks-launches-ai-powered-consumer-insight-solution-personaflow-302091741.html

Someone loading up, like yesterday

cheap copper play this.......

10 Bagger is only £7m wow!

5 bagger £3.5m Mcap

when copper is the talk of the town, expect investors piling on CMRS

cooper grades are outstanding in morroco.

Anyone seen Copper news in Australia?

look at my post on CMRS

Copper resources will be getting attention very soon

CMRS is Valued £700k,

cheapest copper play in the UK market

https://youtu.be/0znlx6-8eu8?si=ykVHNWV2_NRXdOZn